Prisotinol is aminoalkyl-5-pyridinol patented by Ciba-Geigy A.-G. for treatment of angina pectoris. Prisotinol was studied in phase II clinical trials as a cardioprotective agent.

FLOSATIDIL is an antihypertensive drug discontinued in Phase II for angina pectoris.

Transcainide is a new and very potent analog of lidocaine that has been found effective in the treatment of ventricular arrhythmias. In common with other class I antiarrhythmic drugs its main electrophysiologic effect is a reduction of the upstroke velocity of the action potential (Vmax) suggesting a blockade of the sodium channel. The interaction of transcainide with this receptor is reversible and state-dependent. Transcainide characterized by very slow kinetics of binding and unbinding to the activated "open" Na+ channel. Transcainide had been in phase II clinical trial for the treatment of Arrhythmias. However, this development was discontinued.

Pitenodil is a vasodilator.

Tecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. Adenosine is a naturally occurring compound that stimulates all adenosine receptor subtypes in the body, including the A2 adenosine receptor which lowers blood pressure. In non-clinical trials, tecadenoson selectively stimulated the A1 adenosine receptor in the Atrioventricular node (AV node) and slowed the speed of electrical conduction across the AV node, reducing the number of electrical impulses that reached the ventricle, without affecting blood pressure. Clinical studies to date with intravenous tecadenoson suggest that it may slow the speed of AV nodal conduction by selectively stimulating the A1 adenosine receptor, and may avoid blood pressure lowering by not stimulating the A2 adenosine receptor. Thus, it may be possible to use intravenous tecadenoson to convert patients from PSVT to normal sinus rhythm without lowering blood pressure or causing adverse events related to vasodilation such as flushing, palpitations or a headache.

Forasartan (also known as SC-52458) was developed as an orally active, competitive angiotensin (Ang) II subtype 1 (AT1)-receptor antagonist for the treatment of hypertension. Forasartan competes with angiotensin II for binding at the AT1 receptor subtype. It is known that angiotensin II is a vasoconstrictor and stimulates the synthesis and release of aldosterone, and blockage of its effects results in a decrease in systemic vascular resistance. Information about the further development of forasartan is not available.

Fluzoperine was studied as an antiarrhythmic agent. However, information about the current use of this drug is not available.

Yohimbinic acid, also known as yohimbic acid is an indole alkaloid, which was isolated from dried roots of Rauwolfia serpentina. Yohimbinic acid is a potent inhibitor of a human DNA Topoisomerase I and can inhibit cancer cells growth.

Guanclofine was studied as an adrenergic neuron blocking agent.